ThaiPR.NET https://www.thaipr.net/location/florence-italy-and-new-york-ny Press Release Distribution Center of Thailand Fri, 08 May 2026 17:32:31 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer]]> https://www.thaipr.net/en/health_en/3224624 Mon, 15 Aug 2022 14:27:55 +0700 health_en https://www.thaipr.net/en/health_en/3224624 Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrant showing statistically significant efficacy over current standard-of-care (SOC) medications for both the overall […]

The post Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer appeared first on ThaiPR.NET.

]]>